JP2021514011A - Ｅｇｆｒ阻害剤の組合せ医薬製剤およびその使用法 - Google Patents

Ｅｇｆｒ阻害剤の組合せ医薬製剤およびその使用法 Download PDF

Info

Publication number
JP2021514011A
JP2021514011A JP2020566549A JP2020566549A JP2021514011A JP 2021514011 A JP2021514011 A JP 2021514011A JP 2020566549 A JP2020566549 A JP 2020566549A JP 2020566549 A JP2020566549 A JP 2020566549A JP 2021514011 A JP2021514011 A JP 2021514011A
Authority
JP
Japan
Prior art keywords
carbon atoms
egfr
formula
optionally substituted
treat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020566549A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019164949A5 (https=
JP2021514011A5 (https=
Inventor
ナサニエル・エス・グレイ
ドリス・ド・クレルク
ジェボン・ジャン
パシ・ジャンヌ
チリッチ・ト
マイケル・エク
ウンヨン・パク
デイヴィッド・ヘップナー
Original Assignee
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド, デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド filed Critical デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Publication of JP2021514011A publication Critical patent/JP2021514011A/ja
Publication of JPWO2019164949A5 publication Critical patent/JPWO2019164949A5/ja
Publication of JP2021514011A5 publication Critical patent/JP2021514011A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020566549A 2018-02-20 2019-02-20 Ｅｇｆｒ阻害剤の組合せ医薬製剤およびその使用法 Pending JP2021514011A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862632806P 2018-02-20 2018-02-20
US62/632,806 2018-02-20
US201862744083P 2018-10-10 2018-10-10
US62/744,083 2018-10-10
PCT/US2019/018774 WO2019164949A1 (en) 2018-02-20 2019-02-20 Pharmaceutical combinations of egfr inhibitors and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2021514011A true JP2021514011A (ja) 2021-06-03
JPWO2019164949A5 JPWO2019164949A5 (https=) 2022-02-25
JP2021514011A5 JP2021514011A5 (https=) 2022-02-25

Family

ID=67688573

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020566549A Pending JP2021514011A (ja) 2018-02-20 2019-02-20 Ｅｇｆｒ阻害剤の組合せ医薬製剤およびその使用法

Country Status (6)

Country Link
US (1) US20210085688A1 (https=)
EP (1) EP3755337A4 (https=)
JP (1) JP2021514011A (https=)
AU (1) AU2019225807A1 (https=)
CA (1) CA3087797A1 (https=)
WO (1) WO2019164949A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11895006B2 (en) 2018-09-15 2024-02-06 Huawei Technologies Co., Ltd. Communication method, device, and system

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021514011A (ja) * 2018-02-20 2021-06-03 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｅｇｆｒ阻害剤の組合せ医薬製剤およびその使用法
EP3755689B1 (en) 2018-02-20 2023-12-06 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
AU2019225799A1 (en) * 2018-02-20 2020-07-09 Dana-Farber Cancer Institute, Inc. Pharmaceutical combinations of EGFR inhibitors and methods of use thereof
AU2022230397A1 (en) * 2021-03-02 2023-09-21 Dana-Farber Cancer Institute, Inc. Covalent egfr inhibitors and methods of use thereof
US20250197390A1 (en) * 2022-03-16 2025-06-19 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fused heterocyclic compound, and preparation method therefor and medical use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012511054A (ja) * 2008-12-08 2012-05-17 ブイエム ファーマ エルエルシー タンパク質受容体チロシンキナーゼ阻害薬の組成物
JP2013544273A (ja) * 2011-07-27 2013-12-12 アストラゼネカ アクチボラグ ２−（２，４，５−置換−アニリノ）ピリミジン化合物
WO2014160430A1 (en) * 2013-03-13 2014-10-02 Georgetown University Small molecule lrrk2 and erk5 inhibitors
WO2015196072A2 (en) * 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
WO2017177092A1 (en) * 2016-04-07 2017-10-12 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating pi3k-mediated disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070105835A1 (en) * 2005-11-07 2007-05-10 Kazantsev Aleksey G Compositions and methods for modulating poly(ADP-ribose) polymerase activity
EP3399968B8 (en) * 2016-01-07 2021-12-01 Xuanzhu Biopharmaceutical Co., Ltd. Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
JP2021514011A (ja) * 2018-02-20 2021-06-03 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｅｇｆｒ阻害剤の組合せ医薬製剤およびその使用法
AU2019225811A1 (en) * 2018-02-20 2020-07-09 Dana-Farber Cancer Institute, Inc. Degraders of EGFR and methods of use thereof
EP3755689B1 (en) * 2018-02-20 2023-12-06 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
US20200377477A1 (en) * 2018-02-20 2020-12-03 Dana-Farber Cancer Institute, Inc. Degraders of egfr and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012511054A (ja) * 2008-12-08 2012-05-17 ブイエム ファーマ エルエルシー タンパク質受容体チロシンキナーゼ阻害薬の組成物
JP2013544273A (ja) * 2011-07-27 2013-12-12 アストラゼネカ アクチボラグ ２−（２，４，５−置換−アニリノ）ピリミジン化合物
WO2014160430A1 (en) * 2013-03-13 2014-10-02 Georgetown University Small molecule lrrk2 and erk5 inhibitors
WO2015196072A2 (en) * 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
WO2017177092A1 (en) * 2016-04-07 2017-10-12 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating pi3k-mediated disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11895006B2 (en) 2018-09-15 2024-02-06 Huawei Technologies Co., Ltd. Communication method, device, and system

Also Published As

Publication number Publication date
EP3755337A1 (en) 2020-12-30
AU2019225807A1 (en) 2020-07-02
US20210085688A1 (en) 2021-03-25
CA3087797A1 (en) 2019-08-29
WO2019164949A1 (en) 2019-08-29
EP3755337A4 (en) 2021-11-03

Similar Documents

Publication Publication Date Title
JP2021514400A (ja) Ｅｇｆｒの阻害剤およびその使用法
JP6845165B2 (ja) Ｅｇｆｒ阻害剤およびその使用方法
JP2021514011A (ja) Ｅｇｆｒ阻害剤の組合せ医薬製剤およびその使用法
TW202340209A (zh) 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
CN104583195B (zh) 作为酪氨酸激酶抑制剂的含氮杂芳环衍生物
WO2020125513A1 (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
JP2019519476A (ja) Ｅｇｆｒの分解のための二官能性分子、及び使用方法
CN110546145B (zh) 一种氮杂芳基衍生物、其制备方法和在药学上的应用
JP7335275B2 (ja) Ｅｇｆｒの阻害剤およびその使用法
JP2021514012A (ja) Ｅｇｆｒの分解誘導剤およびその使用法
JP2021514398A (ja) Ｅｇｆｒ阻害剤の組合せ医薬製剤およびその使用法
CN113453764B (zh) 7H-吡咯并[2,3-d]嘧啶-4-胺衍生物
US20200377477A1 (en) Degraders of egfr and methods of use thereof
JP2021514397A (ja) Ｅｇｆｒ阻害剤の組合せ医薬製剤およびその使用法
JP2022517745A (ja) ２，４－ジアミノピリミジン誘導体およびその適用
HK40003735B (zh) 用於egfr降解的双功能分子和使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230320

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231016